Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-TNP-2092
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- TenNor Therapeutics Limited
- Target Recruit Count
- 6
- Registration Number
- NCT05074134
- Locations
- πΊπΈ
Pharmaron Clinical Pharmacology Center, Baltimore, Maryland, United States
Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- TenNor Therapeutics Limited
- Target Recruit Count
- 13
- Registration Number
- NCT04294862
- Locations
- πΊπΈ
Rothman Orthopedic Institute, Philadelphia, Pennsylvania, United States
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Phase 2
Completed
- Conditions
- Skin and Subcutaneous Tissue Bacterial InfectionsGram-Positive Bacterial Infections
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- TenNor Therapeutics Limited
- Target Recruit Count
- 120
- Registration Number
- NCT03964493
- Locations
- πΊπΈ
eStudy Site, San Diego, California, United States
News
No news found